Zobrazeno 1 - 10
of 314
pro vyhledávání: '"Beat Thürlimann"'
Autor:
Marcus Vetter, Karin M Rothgiesser, Qiyu Li, Hanne Hawle, Wolfgang Schönfeld, Karin Ribi, Salome Riniker, Roger von Moos, Andreas Trojan, Elena Kralidis, Mathias Fehr, Andreas Müller, Beat Thürlimann
Publikováno v:
Endocrine Oncology, Vol 2, Iss 1, Pp 9-18 (2023)
Objective: CR1447, a novel transdermal formulation of 4-hydroxytestosterone, has aromatase-inhibiting and androgen receptor (AR)-modulating properties (IC50 4.4 nM) with antitumor effects against AR-positive tumor cells in vitro. This trial investiga
Externí odkaz:
https://doaj.org/article/ee02a98a152e445a96fded14df8d50d3
Autor:
Matti Aapro, Fatima Cardoso, Giuseppe Curigliano, Alexandru Eniu, Joseph Gligorov, Nadia Harbeck, Andreas Mueller, Olivia Pagani, Shani Paluch-Shimon, Elzbieta Senkus, Beat Thürlimann, Khalil Zaman
Publikováno v:
Breast, Vol 66, Iss , Pp 145-156 (2022)
Human epidermal growth factor receptor 2 oncogene (HER2-positive) overexpression/amplification occurs in less than 20% of breast cancers and has traditionally been associated with poor prognosis. Development of therapies that target HER2 has signific
Externí odkaz:
https://doaj.org/article/54b99b760e154469b5c8c8eb580c3532
Autor:
Benjamin Kasenda, Miklos Pless, Beat Thürlimann, Stefanie Hayoz, Annina Lea Schenker, Christoph Kopp, Sämi Schär, Roger von Moos
Publikováno v:
BMJ Open, Vol 13, Iss 4 (2023)
Background Premature trial discontinuation and non-publication of trial results are still major issues negatively affecting reliable evidence generation.Objectives To investigate trial completion and publication rate of cancer trials conducted within
Externí odkaz:
https://doaj.org/article/1cb4f34ae76b409fa5320de2cfdbe5d1
Publikováno v:
Breast, Vol 69, Iss , Pp 316-317 (2023)
Externí odkaz:
https://doaj.org/article/6a1b323cb1304ef8a856bf805e443e30
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-6 (2021)
Abstract Background A recent study found an influence of organized mammography screening programmes (MSPs) on geographical and temporal variation of mastectomy rates. We aimed to quantify the effect on the example of one of the cantonal programmes in
Externí odkaz:
https://doaj.org/article/ba6a3e3e0f7a4b7aa5130ec9a04641d7
Autor:
Karin Ribi, Beat Thürlimann, Corinne Schär, Daniel Dietrich, Richard Cathomas, Ursina Zürrer-Härdi, Thomas von Briel, Sandro Anchisi, Pierre Bohanes, Veronika Blum, Philippe von Burg, Meinrad Mannhart, Clemens B. Caspar, Roger von Moos, Michael Mark
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Bone-targeted agents (BTAs) are widely used in the management of patients with bone metastases from solid tumors. Knowledge of the impact of their routine care use on patient-reported pain and bone pain-related quality of life (Qo
Externí odkaz:
https://doaj.org/article/2f4e37bedf8d49deba6179a01a81e7f8
Publikováno v:
Breast, Vol 62, Iss , Pp S2- (2022)
Externí odkaz:
https://doaj.org/article/0e635827091e426980faabd87b5dfe2f
Autor:
Angela Fischer Maranta, Simon Broder, Constanze Fritzsche, Michael Knauer, Beat Thürlimann, Wolfram Jochum, Thomas Ruhstaller
Publikováno v:
Breast, Vol 51, Iss , Pp 120-126 (2020)
Objectives: The proliferative activity of the Ki-67 index is important in decision-making of adjuvant treatments in early breast cancer. Its reliability can be reduced by inter-observer variability. This analysis’ objective is to evaluate the robus
Externí odkaz:
https://doaj.org/article/0a0573cd948a43b3bacc4b949043aaeb
Autor:
Serenella Eppenberger-Castori, Dirk Klingbiel, Thomas Ruhstaller, Daniel Dietrich, Daniel Alexander Rufle, Karin Rothgiesser, Olivia Pagani, Beat Thürlimann
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
Abstract Background The HER2 extracellular domain shed in blood (HER2ECD) is reported to rise and fall in parallel with HER2+ breast cancer behavior. In this study, we evaluated the clinical relevance of plasma HER2ECD values in patients with metasta
Externí odkaz:
https://doaj.org/article/3e2f1998662b4126856dd5c1de79bb5b
Autor:
Sabine Schmid, Dirk Klingbiel, Stefan Aebi, Aron Goldhirsch, Christoph Mamot, Elisabetta Munzone, Franco Nolè, Christian Oehlschlegel, Olivia Pagani, Bernhard Pestalozzi, Christoph Rochlitz, Beat Thürlimann, Roger von Moos, Patrik Weder, Khalil Zaman, Thomas Ruhstaller
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background The impact of HER2-targeted therapy alone followed by the addition of chemotherapy at disease progression (PD) versus upfront combination was investigated by the SAKK 22/99 trial. The aim of this exploratory analysis of the SAKK 2
Externí odkaz:
https://doaj.org/article/3a71b23e5f6e4fdeb49b83bd63c454c7